Scientists found that nasal cells act as a first line of defense against the common cold, working together to block ...

Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including lenacapavir—HIV’s ability to evolve resistance to the breakthrough antiviral.

Baculoviruses are a diverse group of insect viruses that have long served as both biological control agents in agriculture and versatile tools in biotechnology. Their life cycle is marked by two ...

Lenacapavir (LEN) is an antiviral medication used to treat and prevent HIV/AIDS and was first approved for individuals with ...

When a rhinovirus, the most frequent cause of the common cold, infects the lining of our nasal passages, our cells work ...

A new study shows that the body’s early immune response, not the virus itself, often determines how severe a rhinovirus cold ...

The discovery could serve as a starting point for antiviral strategies. A research team at Ruhr University Bochum, Germany, has identified a previously unknown cellular mechanism crucial to the ...

Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...

Using hypertonic saline nasal drops can reduce the length of the common cold in children by two days, according to a study that will be presented at the European Respiratory Society (ERS) Congress in ...

The common cold is typically caused by viruses, most often rhinoviruses, which infect the upper respiratory tract (nose and throat). 1 Zinc has been reported to block the replication of rhinovirus. By ...

Ushikuvirus is a newly identified giant virus that infects amoebas, adding to a growing group of oversized viruses that scientists believe may have played an important role in the emergence of complex ...